In a move centered around bring a data-centric strategy to clinical research, Boston Children’s Hospital has joined TriNetX’s global health research network.
Cambridge, Massachusetts-based TriNetX is a system geared toward healthcare organizations, contract research organizations and biopharma companies. Through membership, such groups can collaborate, improve clinical trial design and refine recruitment techniques.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Boston Children’s went live on the network on February 1.
Network members utilize TriNetX’s cloud-based platform to study patient populations and analyze potential scenarios. Researchers are given access to a health system’s de-identified patient data. CROs and biopharma companies can see the broad data points and trace them back to an individual healthcare organization. Thus, researchers can create potential groups of patients to be recruited into clinical trials.
Overall, the network makes the concept of clinical trials easier for Boston Children’s, Manfred Stapff, TriNetX’s senior vice president and CMO said in a phone interview.
“TriNetX members get more specifically targeted proposals from pharma companies,” he noted. “Boston Children’s will be exposed to more study requests where patients will more likely be available.”
Additionally, Boston Children’s can find ways to work with other network members both inside and outside the United States. Healthcare entities like Ochsner Health System, Banner Health, Children’s Hospital Colorado and Plymouth Hospitals NHS Trust are all part of the TriNetX system.
In a statement, Piotr Sliz, Boston Children’s chief research information officer, said:
Infusing a data-driven approach into the conversation between research institutions and industry provides great efficiencies, but most importantly, it gives our patients the opportunity to potentially participate in clinical trials they otherwise wouldn’t be aware of. Being part of the TriNetX network allows us to collaborate around the globe with other researchers at biopharmaceutical companies who are working on new therapies that our patients need.
Looking ahead, Stapff said Boston Children’s will likely be an advantageous collaboration partner for other pediatric organizations. Non-pediatric institutions can also benefit from working with the hospital.
“We expect that Boston Children’s will also in the future play a big role in the real-world evidence area,” he said.
Photo: pe-art, Getty Images
